Methods of Prognosis for Non-Hodgkin Lymphoma

摘要

Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis.